Početna › Multipli mijelom › New Jersey

Kliničke studije za Multipli mijelom u državi New Jersey

38 studija za Multipli mijelom traži sudionike na lokacijama u državi New Jersey.

Gradovi u državi New Jersey

Službeni tekst studije (engleski)

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

U tijeku regrutacijaFaza 2

Od 60 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06679829

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Local Institution - 0363, Ridgewood

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT05519085

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Hackensack University Medical Center, Hackensack

U tijeku regrutacijaFaza 1/2

Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT04973605

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Astera Cancer Care, East Brunswick

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07518186

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Astera Cancer Care, East Brunswick

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05552222

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

MSK Basking Ridge, Basking Ridge
MSK Monmouth, Middletown
MSK Bergen, Montvale

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05623020

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Hackensack University Medical Center, Hackensack
Rutgers Cancer Institute of New Jersey, New Brunswick

U tijeku regrutacijaFaza 4

Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05201781

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Hackensack Meridian Health - John Theurer Cancer Center, Hackensack

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT03909412

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

John Theurer Cancer Center, Hackensack

U tijeku regrutacijaFaza 2

Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT04661137

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Hackensack Meridian Health, Hackensack
Carol G Simon Cancer Center, Morristown

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

U tijeku regrutacijaFaza 2

Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT06976476

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Rutgers Cancer Institute of New Jersey, New Brunswick

U tijeku regrutacijaFaza 2

Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06297226

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Hackensack University Medical Center, Hackensack

U tijeku regrutacijaFaza 1/2

Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT06988488

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07075185

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Research Site, Hackensack

U tijeku regrutacijaFaza 1/2

Od 18 godina i više · Oba spola · Ažurirano 27. kol 2026. · NCT07681596

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Atlantic Health System Morristown Medical Center, Morristown

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 24. kol 2026. · NCT06152575

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

MSK Basking Ridge, Basking Ridge
MSK Monmouth, Middletown
MSK Bergen, Montvale

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 24. kol 2026. · NCT05020236

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Jefferson Cherry Hill Hospital, Cherry Hill
Sidney Kimmel Cancer Center Washington Township, Sewell

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04566328

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Hackensack University Medical Center, Hackensack

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT05651932

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT07105059

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, East Brunswick

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 14. kol 2026. · NCT07764978

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Consent only), Middletown
Memorial Sloan Kettering Bergen (Consent Only), Montvale

U tijeku regrutacijaOpažajna studija

Od 18 godina i više · Oba spola · Ažurirano 6. kol 2026. · NCT07249528

Mosaic Trial for Stem Cell Transplant Recipients

Hackensack Meridian Health, Nutley

U tijeku regrutacija

Od 18 godina i više · Oba spola · Ažurirano 3. kol 2026. · NCT06960993

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

U tijeku regrutacijaFaza 1/2

Od 18 godina i više · Oba spola · Ažurirano 28. srp 2026. · NCT07099391

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 16. srp 2026. · NCT06121843

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

U tijeku regrutacijaFaza 2

Od 18 godina i više · Oba spola · Ažurirano 6. srp 2026. · NCT06083922

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

U tijeku regrutacijaFaza 2

Od 18 godina i više · Oba spola · Ažurirano 16. lip 2026. · NCT07454382

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Rutgers Cancer Institute of New Jersey, New Brunswick
RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Brunswick

U tijeku regrutacijaRana faza 1

Od 18 godina i više · Oba spola · Ažurirano 29. svi 2026. · NCT04211259

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Rutgers Cancer Institute of New Jersey, New Brunswick

U tijeku regrutacijaFaza 1/2

Od 18 godina i više · Oba spola · Ažurirano 13. svi 2026. · NCT05828511

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Rutgers Cancer Institute of New Jersey /ID# 266833, New Brunswick

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 12. svi 2026. · NCT06896916

A Dietary Study for People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

U tijeku regrutacija

Od 18 godina i više · Oba spola · Ažurirano 5. svi 2026. · NCT07226609

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GSK Investigational Site, Hackensack

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 22. tra 2026. · NCT06679101

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Atlantic Health, Morristown
Rutgers Cancer Institute of New Jersey, New Brunswick

U tijeku regrutacijaFaza 1/2

Od 12 godina i više · Oba spola · Ažurirano 24. ožu 2026. · NCT04988555

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

U tijeku regrutacijaFaza 2

Od 18 godina i više · Oba spola · Ažurirano 4. ožu 2026. · NCT06066346